However, low Apgar scores worse at discriminating infants at risk for mortality for Black infants versus White infants
MONDAY, July 18, 2022 (HealthDay News) — Low Apgar scores are associated with infant mortality across racial groups, but there is variance across groups, according to a study published online July 12 in PLOS Medicine.
Emma Gillette, M.P.H., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues used data from the U.S. National Vital Statistics System data (2016 to 2017) to identify 6.8 million singleton infants without congenital abnormalities, born between 37 and 44 weeks to mothers aged older than 15 years. Associations between low Apgar score and mortality in infants across racial groups were evaluated.
The researchers found that 98.8 percent of infants had normal scores, 0.9 percent had intermediate scores, and 0.3 percent had low Apgar scores. Low-scoring infants had increased odds of infant mortality compared with infants with normal scores. This association varied by race, with adjusted odds ratios of 54.4 in non-Hispanic White, 70.02 in Hispanic, 23.3 in non-Hispanic Black, 100.4 in Asian, and 26.8 in non-Hispanic other infants.
“Low Apgar scores are associated with mortality across racial groups captured by U.S. records, but are worse at discriminating infants at risk of mortality for Black and non-Hispanic non-Asian infants than for White infants,” the authors write. “Further work to understand which components of the score explain differential associations is needed for developing a scoring system that performs equally well across racial groups.”
Insurance Poses Barrier to Virtual Pulmonary Rehabilitation for COPD
Cancer-Attributable Costs High for Seniors, Vary With Cancer Phase, Type, Race
Hispanic Patients Face Delays in Frontotemporal Dementia Diagnosis
MS-Related Mortality Rates Highest in Non-Hispanic Blacks
Extreme Heat Linked to 33 Clinically Reportable Diagnoses
Odds of Stroke Lower Among Black Individuals Who Have Immigrated
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS
Adenotonsillectomy Linked to Increased Odds of Pediatric-Onset MS